Clinical trial
Celiprolol in Patients With Ehlers-Danlos Syndrome, Vascular Type
NCT00190411 · Assistance Publique - Hôpitaux de Paris, Other · Completed
Key facts
| NCT number | NCT00190411 |
|---|---|
| Title | Celiprolol in Patients With Ehlers-Danlos Syndrome, Vascular Type |
| Official title | Prevention of Vascular Complications by BetaBlocker Treatment in Vascular Ehlers-Danlos Syndrome |
| Lead sponsor | Assistance Publique - Hôpitaux de Paris, Other |
| Collaborators | Aventis Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | EHLERS-DANLOS SYNDROME, TYPE IV, AUTOSOMAL DOMINANT, CHROMOSOME 2q31.2 DELETION SYNDROME |
| Intervention type | Drug |
| Interventions | celiprolol, Control |
| Enrollment | 54 |
| Start date | Oct 1, 2003 |
| Primary completion | Apr 1, 2011 |
| Completion | Apr 1, 2011 |
| First posted | Sep 19, 2005 |
| Last update posted | Jan 16, 2013 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: